Warning letter
Boehringer Ingelheim Pharma GMBH & Co: warning letter of May 6, 2013
FDA warning letter 393563 · Center for Drug Evaluation and Research
Key facts
| Reference number | 393563 |
|---|---|
| Company | Boehringer Ingelheim Pharma GMBH & Co |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | May 6, 2013 |
| Posted date | May 6, 2013 |
| Issuing office | Center for Drug Evaluation and Research |
| Product type | Drugs |
| CFR sections cited | 211.192, 211.165(f) |
| Inspection city | Ingelheim am Rhein |
| Inspection start date | Nov 5, 2012 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: